Element Biosciences, where courage meets possibility
We’re passionate about building new and differentiated technologies that will disrupt the genomics industry. We pursue rigorous science that supports data-driven decisions in ever-evolving markets. We take risks to challenge the status quo. We celebrate our successes and learn from our failures. We’re committed to empowering customers with unprecedented freedom to study biology.
​
We’re excited to announce the close of a Series B financing round, which provides the fuel to ramp up product development activities and hiring in 2020!
Every element of a DNA sequencer – reimagined.
Genetic sequencing has become an increasingly powerful tool to understand biology and improve human life. Element Biosciences is creating a brand-new DNA sequencing platform to meet diverse and ever-changing needs in this dynamic market.
Element Biosciences Raises $80M in Series B Financing to Accelerate Development of a New DNA Sequencing Platform
SAN DIEGO, Calif. — Element Biosciences today announced the close of a Series B financing round of $80.3 million, with participation from new investors Fidelity Management & Research Company and JS Capital LLC, as well as existing investors Foresite Capital and Venrock. To date, the company has raised a total of more than $100 million. Proceeds from the financing will be used to accelerate the development of high-quality, low-cost, and easy-to-use genomic sequencing solutions.
Careers
Our team of professionals is here to inspire and impress the industry with unique ideas and abilities - and to welcome new ones.
